Final follow-up results suggest Opdivo and Yervoy could be close to a cure for some people with advanced melanoma, shifting how doctors administer follow-up care.

Results presented at ESMO showed tumor response rates that matched the bar set by analysts for success. But they may not yet be enough to dispel doubts around TIGIT as a target.

Three drug startups collectively raised more than $700 million in initial public offerings Thursday, a flurry of activity after a largely fallow summer in which few biotechnology companies made the ...

Today, a brief rundown of news from Roche and Gilead Sciences, as well as updates from Eli Lilly, Biogen and GSK that you may have missed. Recent biotech company acquisitions have put emerging ...

Months after winning approval of a new vaccine for respiratory syncytial virus, Moderna is acknowledging that wresting market share from its two competitors may be more difficult than it thought.

FSHD, or facioscapulohumeral muscular dystrophy, is a neuromuscular disorder characterized by muscle weakness in the face, shoulders and arms. It’s primarily caused ...

Moderna will cut R&D spending by 20% and trim its pipeline as part of a strategic overhaul that will shift its research focus and put more resources into products that are either nearing approvals or ...

Vironexis Biotherapeutics emerged from stealth with plans to start what it claims will be the first-ever clinical trial testing a cancer immunotherapy delivered with the help of an adeno-associated ...